Hydrogen sulfide (H 2 S) is a crucial signaling molecule involved in regulating inflammation, oxidative stress, and metabolism. S-propargyl-cysteine (SPRC) modulates endogenous H 2 S production pathways by influencing relevant enzymes, presenting a potential therapeutic approach for conditions associated with abnormal sulfide levels. This study investigated the safety and pharmacokinetic properties of SPRC in a Good Laboratory Practice 28-day oral toxicity study in rats, including safety pharmacology and gene toxicity assessments. SPRC exhibited favorable pharmacokinetic characteristics and safety margins, with a No Observed Adverse Effect Level (NOAEL) of 37.5 mg/kg, translating to an estimated 8.5-fold therapeutic window. These initial toxicology findings, coupled with SPRC’s pharmacological effects on the sulfide signaling axis, support its progression to first-in-human clinical trials for further benefit risk evaluation. The promising safety and pharmacokinetic profile of SPRC underscores its therapeutic potential and justifies additional clinical investigation for disorders linked to aberrant sulfide signaling. To comprehensively assess the therapeutic utility of SPRC, further preclinical safety evaluations and early phase clinical studies are warranted. These investigations will provide insights into SPRC’s potential to address unmet medical needs in various disease areas related to disrupted sulfur metabolism and hydrogen sulfide biology.
Kimura, H. (2010) Hydrogen Sulfide as a Physiological Mediator: Its Function and Therapeutic Applications. Folia Pharmacologica Japonica , 136, 335-339. https://doi.org/10.1254/fpj.136.335
Kimura, H. (2024) Hydrogen Sulfide (H 2 S)/Polysulfides (H 2 S n ) Signalling and TRPA1 Channels Modification on Sulfur Metabolism. Biomolecules , 14, Article 129. https://doi.org/10.3390/biom14010129
Li, L., Rose, P. and Moore, P.K. (2011) Hydrogen Sulfide and Cell Signaling. Annual Review of Pharmacology and Toxicology , 51, 169-187. https://doi.org/10.1146/annurev-pharmtox-010510-100505
Wang, R., Cai, J., Chen, K., Zhu, M., Li, Z., Liu, H., et al. (2022) STAT3-NAV2 Axis as a New Therapeutic Target for Rheumatoid Arthritis via Activating SSH1L/Cofilin-1 Signaling Pathway. Signal Transduction and Targeted Therapy , 7, Article No. 209. https://doi.org/10.1038/s41392-022-01050-7
Zhu, M., Ding, Q., Lin, Z., Fu, R., Zhang, F., Li, Z., et al. (2023) New Targets and Strategies for Rheumatoid Arthritis: From Signal Transduction to Epigenetic Aspect. Biomolecules , 13, Article 766. https://doi.org/10.3390/biom13050766
Ma, G., Zhang, L., Zhang, P., Bao, X., Zhou, N., Shi, Q., et al. (2014) Physicochemical Characteristics and Gastrointestinal Absorption Behaviors of s -Propargyl-Cysteine, a Potential New Drug Candidate for Cardiovascular Protection and Antitumor Treatment. Xenobiotica , 45, 322-334. https://doi.org/10.3109/00498254.2014.980369
Wen, Y. and Zhu, Y. (2015) The Pharmacological Effects of S-Propargyl-Cysteine, a Novel Endogenous H 2 S-Producing Compound. In: Moore, P. and Whiteman, M., Eds., Chemistry , Biochemistry and Pharmacology of Hydrogen Sulfide , Springer, 325-336. https://doi.org/10.1007/978-3-319-18144-8_16
Li, L., Hsu, A. and Moore, P.K. (2009) Actions and Interactions of Nitric Oxide, Carbon Monoxide and Hydrogen Sulphide in the Cardiovascular System and in Inflammation—A Tale of Three Gases! Pharmacology & Therapeutics , 123, 386-400. https://doi.org/10.1016/j.pharmthera.2009.05.005
Zaorska, E., Tomasova, L., Koszelewski, D., Ostaszewski, R. and Ufnal, M. (2020) Hydrogen Sulfide in Pharmacotherapy, Beyond the Hydrogen Sulfide-Donors. Biomolecules , 10, Article 323. https://doi.org/10.3390/biom10020323
Andrés, C.M.C., Pérez de la Lastra, J.M., Andrés Juan, C., Plou, F.J. and Pérez-Lebeña, E. (2023) Chemistry of Hydrogen Sulfide—Pathological and Physiological Functions in Mammalian Cells. Cells , 12, Article 2684. https://doi.org/10.3390/cells12232684
Li, W., Ma, F., Zhang, L., Huang, Y., Li, X., Zhang, A., et al. (2016) S‐Propargyl-Cysteine Exerts a Novel Protective Effect on Methionine and Choline Deficient Diet-Induced Fatty Liver via Akt/Nrf2/HO‐1 Pathway. Oxidative Medicine and Cellular Longevity , 2016, Article ID: 4690857. https://doi.org/10.1155/2016/4690857
Cao, X., Ding, L., Xie, Z., Yang, Y., Whiteman, M., Moore, P.K., et al. (2019) A Review of Hydrogen Sulfide Synthesis, Metabolism, and Measurement: Is Modulation of Hydrogen Sulfide a Novel Therapeutic for Cancer? Antioxidants & Redox Signaling , 31, 1-38. https://doi.org/10.1089/ars.2017.7058
Wang, W., Ge, T., Chen, X., Mao, Y. and Zhu, Y. (2020) Advances in the Protective Mechanism of NO, H 2 S, and H 2 in Myocardial Ischemic Injury. Frontiers in Cardiovascular Medicine , 7, Article 588206. https://doi.org/10.3389/fcvm.2020.588206
Wang, Y., Ngowi, E.E., Wang, D., Qi, H., Jing, M., Zhang, Y., et al. (2021) The Potential of Hydrogen Sulfide Donors in Treating Cardiovascular Diseases. International Journal of Molecular Sciences , 22, Article 2194. https://doi.org/10.3390/ijms22042194
Yu, Y., Wang, Z., Ding, Q., Yu, X., Yang, Q., Wang, R., et al. (2021) The Preparation of a Novel Poly(Lactic Acid)-Based Sustained H 2 S Releasing Microsphere for Rheumatoid Arthritis Alleviation. Pharmaceutics , 13, Article 742. https://doi.org/10.3390/pharmaceutics13050742
Zhu, C., Liu, Q., Li, X., Wei, R., Ge, T., Zheng, X., et al. (2022) Hydrogen Sulfide: A New Therapeutic Target in Vascular Diseases. Frontiers in Endocrinology , 13, Article 934231. https://doi.org/10.3389/fendo.2022.934231
Zheng, Y., Liu, H., Ma, G., Yang, P., Zhang, L., Gu, Y., et al. (2011) Determination of S-Propargyl-Cysteine in Rat Plasma by Mixed-Mode Reversed-Phase and Cation-Exchange HPLC–MS/MS Method and Its Application to Pharmacokinetic Studies. Journal of Pharmaceutical and Biomedical Analysis , 54, 1187-1191. https://doi.org/10.1016/j.jpba.2010.11.027
Zheng, Y., Zhu, J., Ma, G., Zhu, Q., Yang, P., Tan, B., et al. (2012) Preclinical Assessment of the Distribution, Metabolism, and Excretion of S-Propargyl-Cysteine, a Novel H 2 S Donor, in Sprague-Dawley Rats. Acta Pharmacologica Sinica , 33, 839-844. https://doi.org/10.1038/aps.2012.15
Zheng, Y., Xu, J., Ma, G., Zhang, J., Zhu, Q., Liu, H., et al. (2011) Bioavailability and Pharmacokinetics of S-Propargyl-L-Cysteine, a Novel Cardioprotective Agent, after Single and Multiple Doses in Beagle Dogs. Xenobiotica , 42, 304-309. https://doi.org/10.3109/00498254.2011.617848
Nair, A. and Jacob, S. (2016) A Simple Practice Guide for Dose Conversion between Animals and Human. Journal of Basic and Clinical Pharmacy , 7, 27-31. https://doi.org/10.4103/0976-0105.177703
Pan, L., Liu, X., Gong, Q. and Zhu, Y. (2011) S -Propargyl-Cysteine (SPRC) Attenuated Lipopolysaccharide-Induced Inflammatory Response in H 9 C 2 Cells Involved in a Hydrogen Sulfide-Dependent Mechanism. Amino Acids , 41, 205-215. https://doi.org/10.1007/s00726-011-0834-1
Li, P., Li, Z.M., Zhang, B.S., et al. (2024) S-Propargyl-Cysteine Promotes the Stability of Atherosclerotic Plaque via Maintaining Vascular Muscle Contractile Phenotype. Frontiers in Cell and Developmental Biology , 11, Article 1291170. https://doi.org/10.3389/fcell.2023.1291170
Blank, M., et al . (2009) Review of Qualification Data for Biomarkers of Nephrotoxicity Submitted by the Predictive Safety Testing Consortium. https://www.fda.gov/media/87781/download
Kashfi, K. and Olson, K.R. (2013) Biology and Therapeutic Potential of Hydrogen Sulfide and Hydrogen Sulfide-Releasing Chimeras. Biochemical Pharmacology , 85, 689-703. https://doi.org/10.1016/j.bcp.2012.10.019
Heimbach, T., Lakshminarayana, S.B., Hu, W. and He, H. (2009) Practical Anticipation of Human Efficacious Doses and Pharmacokinetics Using in Vitro and Preclinical in Vivo Data. The AAPS Journal , 11, 602-614. https://doi.org/10.1208/s12248-009-9136-x